This buy now, pay later stock is a high-quality growth story with big upside, Loop Capital says
The firm initiated coverage of the buy now, pay later company with a buy rating.
RBC Capital has assigned an outperform rating to Roche Holding and set a price target of CHF400.00, citing the company's robust base business and promising pipeline as key drivers. The stock, currently trading at $54.07, boasts a market capitalization of $351.77 billion and has generated a 29.7% return over the past year. RBC Capital believes the pipeline holds greater potential than currently reflected by analysts' models, particularly highlighting giredestrant as a potential CHF14 billion opportunity.
The drug targets a specific breast cancer population, offering extended adjuvant treatment. Despite trading near an all-time high valuation, RBC Capital remains optimistic about Roche's prospects, expecting further re-rating. The company faces no immediate competition from existing treatments, positioning Roche as a quality compounder with sustained growth potential through 2030 and beyond.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
